Isotype
Human Therapeutic Antibody
Description
CDC-Enhanced Figitumumab is a Fc-modified anti-IGF1 Receptor therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Figitumumab, Figitumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Non-small cell lung cancers (NSCLC)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Insulin Like Growth Factor 1 Receptor
Background
This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014]
Alternative Names
Cixutumumab;947687-12-9;IMC-A12;NSC742460;IGF1R;insulin-like growth factor 1 receptor;CD221;IGFIR;IGFR;JTK13;MGC18216;IGF-I receptor;soluble IGF1R variant 1;soluble IGF1R variant 2;insulin-like growth factor I receptor;MGC142170;MGC142172;
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human Therapeutic Antibody
Description
Recombinant monoclonal antibody to IGF1 Receptor. Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).
Indication
Non-small cell lung cancers (NSCLC)
